This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Scopus Google Scholar Articles by Moreira, T. Articles by Bond, J. Social Bookmarking                         What's this?

Regulatory Objectivity in Action

Mild Cognitive Impairment and the Collective Production of Uncertainty

School of Applied Social Sciences, Durham University, 32 Old Elvet, Durham DH1 3HN, UK,, tiago.moreira{at}durham.ac.uk

Carl May

Institute of Health and Society, 21 Claremont Place, Newcastle University, Newcastle Upon Tyne NE2 4AA, UK, C.R.May{at}ncl.ac.uk

John Bond

Institute of Health and Society, 21 Claremont Place, Newcastle University, Newcastle Upon Tyne NE2 4AA, UK, John.Bond{at}ncl.ac.uk

In this paper, we investigate recent changes in the definition and approach to Alzheimer’s disease brought about by growing clinical, therapeutic and regulatory interest in the prodromal or preclinical aspects of this condition. In the last decade, there has been an increased interest in the biomolecular and epidemiological characterization of pre-clinical dementia. It is argued that early diagnosis of dementia, and particularly of Alzheimer‘s disease, will facilitate the prevention of dementing processes and lower the prevalence of the condition in the general population. The search for a diagnostic category or biomarker that would serve this purpose is an ongoing but problematic endeavour for research and clinical communities in this area. In this paper, we explore how clinical and research actors, in collaboration with regulatory institutions and pharmaceutical companies, come to frame these domains as uncertainties and how they re-deploy uncertainty in the ‘collective production’ of new diagnostic conventions and bioclinical standards. While drawing as background on ethnographic, documentary and interview data, the paper proposes an in-depth, contextual analysis of the proceedings of an international meeting organized by the Peripheral and Central Nervous System Drug Advisory Committee of the US Food and Drug Administration to discuss whether or not a particular diagnostic convention — mild cognitive impairment — exists and how best it ought to be studied. Based on this analysis we argue that the deployment of uncertainty is reflexively implicated in bioclinical collectives’ search for rules and conventions, and furthermore that the collective production of uncertainty is central to the ‘knowledge machinery’ of regulatory objectivity.

Key Words: Alzheimer’s disease • biomedicine • diagnostic convention • mild cognitive impairment • uncertainty

Social Studies of Science, Vol. 39, No. 5, 665-690 (2009)
DOI: 10.1177/0306312709103481


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. Rabeharisoa and P. Bourret Staging and Weighting Evidence in Biomedicine: Comparing Clinical Practices in Cancer Genetics and Psychiatric Genetics Social Studies of Science, October 1, 2009; 39(5): 691 - 715. [Abstract] [PDF]